Pharma BD Deal Intelligence
Merger requires approval of at least 66-2/3% of votes cast by Sernova shareholders plus court and regulatory approvals; BetaNova intends to seek Nasdaq listing…
Shareholders of each company will own approximately 50% of BetaNova on a non-diluted basis; US$10 million non-brokered convertible note financing from existing…
Source summaries from our enrichment pipeline; follow links for originals.
All 3 sources with sentiment breakdown →
Seraxis Holdings, Inc. and Sernova Biotherapeutics Inc. entered a definitive merger agreement on September 8, 2026 to combine under the name BetaNova Biotherapeutics, Inc., an integrated islet cell-replacement company in type 1 diabetes. The all-stock transaction is structured as a statutory plan of arrangement under the British Columbia Business Corporations Act; shareholders of each company will hold approximately 50% of BetaNova on a non-diluted basis, and outstanding Sernova convertible securities will be exchanged for comparable Seraxis securities. No aggregate transaction value was disclosed. Alongside the merger the parties secured a US$10 million non-brokered convertible note financing from existing insider shareholders of both companies, convertible into non-voting BetaNova common stock at closing and open to additional qualified investors through September 30, 2026. The combination pairs the Sernova Cell Pouch Bio-hybrid Organ, an implantable and retrievable device, with the Seraxis stem cell-derived pancreatic islet programs and in-house cGMP manufacturing. Lead asset SR-02, an allogeneic stem cell-derived pancreatic islet therapy, holds an FDA-cleared IND with first patient dosing in a Phase 1/2 study expected in Q1 2027; SR-03 adds gene edits intended to confer immune evasion without chronic immunosuppression, with IND submission targeted for H2 2027. Jonathan Rigby (Sernova CEO) is designated CEO of BetaNova and Will Rust (Seraxis CEO) President and Chief Scientific Officer. Closing requires approval of at least 66-2/3% of votes cast by Sernova shareholders plus court and regulatory approvals, and is expected in November 2026; BetaNova intends to seek a Nasdaq listing in Q1 2027. NOTE: ingested at pending_review by bd-enrichment 2026-09-09.
← Browse all deals · How we score deals
More: 2026 deals